Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study.
Ruano-Ravina A, Provencio M, Calvo de Juan V, Carcereny E, Estival A, Rodríguez-Abreu D, Benítez G, López-Castro R, Belver M, Guirado-Risueño M, Guirao-Rubio C, Blasco A, Massutí B, Ortega AL, Cobo M, Mosquera-Martínez J, Aguado de la Rosa C, Bosch-Barrera J, Sánchez-Gastaldo A, Del Barco Morillo E, Juan Ó, Dómine M, Trigo JM, Pereiro Corbacho D, Oramas J. Ruano-Ravina A, et al. Transl Lung Cancer Res. 2021 Oct;10(10):3902-3911. doi: 10.21037/tlcr-21-559. Transl Lung Cancer Res. 2021. PMID: 34858780 Free PMC article.
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R. Karachaliou N, et al. Sci Rep. 2015 Dec 7;5:17499. doi: 10.1038/srep17499. Sci Rep. 2015. PMID: 26639561 Free PMC article.
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Costa EC, Lee C, Puig M, Kraemer S, Schnell D, Rosell R. Moran T, et al. Lung Cancer. 2017 Jun;108:154-160. doi: 10.1016/j.lungcan.2017.03.009. Epub 2017 Mar 22. Lung Cancer. 2017. PMID: 28625629 Clinical Trial.
Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.
Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R. Morán T, et al. Oncotarget. 2018 Jun 5;9(43):27074-27086. doi: 10.18632/oncotarget.25478. eCollection 2018 Jun 5. Oncotarget. 2018. PMID: 29930751 Free PMC article.
Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study).
Provencio M, Carcereny E, Rodríguez-Abreu D, López-Castro R, Guirado M, Camps C, Bosch-Barrera J, García-Campelo R, Ortega-Granados AL, González-Larriba JL, Casal-Rubio J, Domine M, Massutí B, Sala MÁ, Bernabé R, Oramas J, Del Barco E. Provencio M, et al. Transl Lung Cancer Res. 2019 Aug;8(4):461-475. doi: 10.21037/tlcr.2019.08.05. Transl Lung Cancer Res. 2019. PMID: 31555519 Free PMC article.
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
Garcia-Campelo R, Arrieta O, Massuti B, Rodriguez-Abreu D, Granados ALO, Majem M, Vicente D, Lianes P, Bosch-Barrera J, Insa A, Dómine M, Reguart N, Guirado M, Sala MÁ, Vázquez-Estevez S, Caro RB, Drozdowskyj A, Verdú A, Karachaliou N, Molina-Vila MA, Rosell R; Spanish Lung Cancer Group (SLCG). Garcia-Campelo R, et al. Lung Cancer. 2020 Dec;150:62-69. doi: 10.1016/j.lungcan.2020.09.018. Epub 2020 Oct 3. Lung Cancer. 2020. PMID: 33070053 Clinical Trial.
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial.
Romero A, Jantus-Lewintre E, García-Peláez B, Royuela A, Insa A, Cruz P, Collazo A, Pérez Altozano J, Vidal OJ, Diz P, Cobo M, Hernández B, Vázquez Estevez S, Benítez G, Guirado M, Majem M, Bernabé R, Ortega AL, Blasco A, Bosch-Barrera J, Jurado JM, García González J, Viteri S, Garcia Giron C, Massutí B, Lopez Martín A, Rodriguez-Festa A, Calabuig-Fariñas S, Molina-Vila MÁ, Provencio M. Romero A, et al. Mol Oncol. 2021 Jan;15(1):43-56. doi: 10.1002/1878-0261.12832. Epub 2020 Nov 13. Mol Oncol. 2021. PMID: 33107189 Free PMC article.
SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020).
Nadal E, Bosch-Barrera J, Cedrés S, Coves J, García-Campelo R, Guirado M, López-Castro R, Ortega AL, Vicente D, de Castro-Carpeño J. Nadal E, et al. Clin Transl Oncol. 2021 May;23(5):980-987. doi: 10.1007/s12094-020-02532-2. Epub 2021 Feb 4. Clin Transl Oncol. 2021. PMID: 33538989 Free PMC article. Review.
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
Provencio M, Terrasa J, Garrido P, Campelo RG, Aparisi F, Diz P, Aguiar D, García-Giron C, Hidalgo J, Aguado C, González JG, Esteban E, Gómez-Aldavarí L, Moran T, Juan O, Chara LE, Marti JL, Castro RL, Ortega AL, Moreno EM, Coves J, Sánchez Peña AM, Bosch-Barrera J, Gastaldo AS, Núñez NF, Del Barco E, Cobo M, Isla D, Majem M, Navarro F, Calvo V. Provencio M, et al. BMC Cancer. 2021 Mar 6;21(1):230. doi: 10.1186/s12885-021-07922-5. BMC Cancer. 2021. PMID: 33676426 Free PMC article.
132 results